Skip to main content

Table 2 Changes in the lipid profile and clinical characteristics between baseline and post-treatment values

From: Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

  Intention to treat analysis N = 437
  Baseline Final Percent change
Triglycerides (mM/l) 3.01 ± 0.7 1.61 ± 0.8 -44 ± 33*
HDL Cholesterol (mM/l) 0.91 ± 0.1 0.98 ± 0.4 10 ± 52*
Non-HDL cholesterol (mM/l) 4.57 ± 0.9 3.61 ± 1.5 -19 ± 36*
Cholesterol (mM/l) 5.5 ± 0.9 4.57 ± 1.8 -14.9 ± 35*
LDL Cholesterol (mM/l) 3.1 ± 0.9 2.8 ± 1.3 -5.4 ± 59*
  1. Mean ± standard deviation are presented. *p < 0.001 To convert to mg/dl multiple by 89 To convert to mg/dl multiple by 38